This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, E.
Right arrow Articles by Mufson, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, E.
Right arrow Articles by Mufson, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2003, p. 1151-1153, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1151-1153.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Lack of Synergy of Erythromycin Combined with Penicillin or Cefotaxime against Streptococcus pneumoniae In Vitro

Eugene Lin,{dagger} Ronald J. Stanek, and Maurice A. Mufson*

Department of Medicine, Marshall University School of Medicine, Huntington, West Virginia 25701-3655

Received 19 June 2002/ Returned for modification 20 October 2002/ Accepted 25 November 2002

We investigated a possible synergistic effect of a macrolide and ß-lactams against Streptococcus pneumoniae strains with different resistance profiles. Checkerboard and time-kill assays of erythromycin combined with penicillin or cefotaxime essentially showed indifference, suggesting that these antibiotics in combinations in vitro act substantially as individuals in their activity against S. pneumoniae.

* Corresponding author. Mailing address: Department of Medicine, Marshall University School of Medicine, 1600 Medical Center Dr., Suite G500, Huntington, WV 25701-3655. Phone: (304) 691-1050. Fax: (304) 691-1693. E-mail: mufson{at}marshall.edu.

{dagger} Present address: Mayo Clinic School of Medicine, Rochester, MN 55905.

Antimicrobial Agents and Chemotherapy, March 2003, p. 1151-1153, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1151-1153.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Paul, M., Nielsen, A. D., Gafter-Gvili, A., Tacconelli, E., Andreassen, S., Almanasreh, N., Goldberg, E., Cauda, R., Frank, U., Leibovici, L., on behalf of the TREAT Study Group, (2007). The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 30: 525-531 [Abstract] [Full Text]  
  • Weiss, K., Tillotson, G. S. (2005). The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia. Chest 128: 940-946 [Abstract] [Full Text]  
  • Haas, W., Sublett, J., Kaushal, D., Tuomanen, E. I. (2004). Revising the Role of the Pneumococcal vex-vncRS Locus in Vancomycin Tolerance. J. Bacteriol. 186: 8463-8471 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»